| Tomudex (raltitrexed) / Pfizer, AstraZeneca |
| Completed | 2 | 100 | | raltitrexed plus oxaplatin ;raltitrexed plus Irinotecan | The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, Zhejiang Provincial Natural Science Fund (LY13H160007) | advanced colorectal cancer | | | | |
ChiCTR-IIR-17013316: A randomized, open, multicenter phase II study for efficacy and safety of Thymalfasin Alpha-1 combined with raltitrexed in patienr with advanced colorectal cancer |
|
|
| Recruiting | 2 | 60 | | Thymalfasin Alpha-1 and raltitrexed ;raltitrexed | Shanghai EAST Hospital; No 1800 Yuntai Rd, Shanghai, IIS | colorectal cancer | | | | |
ChiCTR1900020485: Phase II study for bevacizumab combined with S-1 and raltitrexed in the treatment of metastatic colorectal cancer resistant to 5-fluorouracil / oxaliplatin /irinotecan |
|
|
| Recruiting | 2 | 43 | | bevacizumab combined with S-1 and raltitrexed | West China Hospital of Sichuan University; West China Hospital, Sichuan University, researchers | metastatic colorectal cancer | | | | |
NCT04499586: A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 30 | RoW | Radiotherapy Combined With Raltitrexed and Irinotecan | Fudan University | Recurrent Colorectal Cancer | 08/20 | 12/20 | | |
ChiCTR1800018400: A Multicenter, Open, Randomized Controlled Phase II Study for the Efficacy and Safety of Raltitrexed Combined with Vinorelbine and Capecitabine Combined with Vinorelbine in the Second-line Treatment of Advanced Breast Cancer |
|
|
| Not yet recruiting | 2 | 158 | | Raltitrexed Combined with Vinorelbine ;Capecitabine Combined with Vinorelbine | The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised | Advanced Breast Cancer | | | | |
| Not yet recruiting | 2 | 66 | NA | cTACE-HAIC, OXRI | Beijing Cancer Hospital | Transarterial Chemoembolization, Hepatocellular Carcinoma | 10/21 | 10/22 | | |
NCT04241731: A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Raltitrexed, Cetuximab | Jiangsu Cancer Institute & Hospital | Colorectal Cancer | 11/21 | 11/21 | | |
NCT03585530: Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus |
|
|
| Active, not recruiting | 2 | 32 | RoW | raltitrexed | Huai'an First People's Hospital | Esophagus Squamous Cell Carcinoma | 01/22 | 03/22 | | |
NCT03126071: Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Raltitrexed, Irinotecan, Oxaliplatin, Bevacizumab, Avastin | Jiangsu Cancer Institute & Hospital | Advanced Colorectal Cancer | 08/22 | 02/23 | | |
NCT04581876: The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 120 | RoW | raltitrexed for injection, raltitrexed, nab-paclitaxel, albumin-bound paclitaxel | Fudan University | Pancreatic Cancer, Chemotherapy Effect | 09/22 | 03/23 | | |
ChiCTR1900027159: Efficacy and safety of irinotecan combined with retitroxel regimen in salvage chemotherapy for advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 80 | | Irinotecan ;Irinotecan plus raltitrexed | The First People's Hospital of Yancheng City, Jiangsu Province; The First People's Hospital of Yancheng, The fund of applying | Advanced esophageal squamous cell cancer | | | | |
| Recruiting | 2 | 50 | RoW | Raltitrexed combined with oxaplatin, Sai Wei Jian | Second Affiliated Hospital, School of Medicine, Zhejiang University | Cholangioadenoma | 12/22 | 12/23 | | |
NCT06427005: Fruquintinib Plus S-1 and Raltitrexed (RSF) for mCRC |
|
|
| Recruiting | 2 | 66 | RoW | Fruquintinib, Elunate, S-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, raltitrexed, thymidylate synthase inhibitor | West China Hospital | Fruquintinib, S-1, Raltitrexed | 06/24 | 12/24 | | |
NCT04582981: Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 136 | RoW | Fruquintinib and raltitrexed, F and R, Fruquintinib, F | Fudan University, Shanxi Province Cancer Hospital | Advanced Colorectal Carcinoma | 06/23 | 12/23 | | |
NCT05160896: SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Raltitrexed, Sai Wei Jian, Irinotecan, CPT-11, Bevacizumab, Avastin, Cetuximab, ERBITUX | Second Affiliated Hospital, School of Medicine, Zhejiang University | Advanced Metastatic Colorectal Cancer | 06/23 | 06/23 | | |
ChiCTR2100053431: Raltitrexed + Oxaliplatin (SALOX) plus Bevacizumab as the First Line Treatment in Patients with Advanced Colorectal Cancer: An Open-Label, Multicenter, Prospective Study |
|
|
| Recruiting | 2 | 90 | | Raltitrexed 3 mg/m^2 + Oxaliplatin 130 mg/m^2 + Bevacizumab 7.5 mg/kg | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Self-funded | Colorectal cancer | | | | |
NCT05435313: Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy |
|
|
| Active, not recruiting | 2 | 39 | RoW | HAIC, Fruquintinib, Tislelizumab, Raltitrexed, Oxaliplatin, Irinotecan | Fudan University | Colorectal Cancer | 01/24 | 02/24 | | |
ChiCTR2100044072: Efficacy and safety of TPF induction chemotherapy regimen containing raltitrexed in locally advanced head and neck squamous cell carcinoma |
|
|
| Recruiting | 2 | 70 | | TPF induction chemotherapy regimen | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Hope Run Special Fund of Cancer Foundation of China | Locally advanced head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) | | | | |
NCT06441019: Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | RoW | HAIC（Oxaliplatin+ Raltitrexed）、TQB2868、Ramucirumab | Fudan University | Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab | 05/25 | 05/26 | | |
NCT06475287: HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | RoW | HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450 | Fudan University | Hepatocellular Carcinoma | 07/25 | 07/26 | | |
TORCH-R, NCT05628038: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer |
|
|
| Recruiting | 2 | 93 | RoW | PD-1 antibody, Toripalimab, Capecitabine, Xeloda, 5FU, folinic acid, Oxaliplatin, Irinotecan, Raltitrexed, Radiation | Fudan University | Recurrent Rectal Cancer | 12/24 | 12/25 | | |
ChiCTR2200066208: Peripheral blood ctDNA second-generation sequencing to guide RAS/BRAF wild type: A clinical study of cetuximab re-challenge in patients with metastatic colorectal cancer |
|
|
| Not yet recruiting | 2 | 27 | | Cetuximab + Sindilizumab + Raltitrexed | Anhui Cancer Hospital; Anhui Cancer Hospital, Beijing Baikouen Charity Foundation | Colorectal Cancer | | | | |
ChiCTR2300068003: Clinical study of regorafenib combined with PD-1/PD-L1 monoclonal antibody and local c-TACE in the treatment of MSS advanced colorectal cancer with liver metastasis |
|
|
| Not yet recruiting | 2 | 35 | | Interventional protocol: regorafenib and PD-1/PD-L1 treatment within 1 week before liver c-TACE, intraoperative administration: raltitrexed 4mg. | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, Self-funded | MSS type advanced colorectal cancer with liver metastasis | | | | |
ChiCTR-ONC-12002767: A Study of the Combination of Raltitrexed and Irinotecan Every Two Weeks as 2nd Line Treatment of Metastatic Colorectal Cancer |
|
|
| Completed | 1/2 | 30 | | Raltitrexed and Irinotecan | West China Hospital, Sichuan University; Level of the institution：, Nanjing Chia Tai Tianqing Pharmaceutical Co.,Ltd | Colorectal Cancer | | | | |
ChiCTR1900021702: Postoperative radiotherapy combined with raltitrexed for gastric cancer patients |
|
|
| Not yet recruiting | 1/2 | 60 | | Concurrent chemoradiation | The Second Affiliated Hospital of Soochow University; The Second Affiliated Hospital of Soochow University, None | Gastric Cancer | | | | |
NCT05426811: Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 50 | NA | Regorafenib, Stivarga, Raltitrexed, Sai wei jian | China Medical University, China, The People's Hospital of Liaoning Province, Anshan Tumor Hospital, The First Affiliated Hospital of Dalian Medical University, The Second Affiliated Hospital of Dalian Medical University, Benxi Cental Hospital | Regorafenib, Raltitrexed, Colorectal Neoplasms, Third-line Treatment | 07/25 | 12/25 | | |
